Taxol/ Carboplatin as First Line Therapy in Patients With Epithelial Ovarian Cancer
  • Phase

    Phase 2
  • Study Type

  • Status

    Completed No Results Posted
  • Study Participants

The combination of paclitaxel and carboplatin in a three weeks schedule has emerged as the current standard approach for the adjuvant treatment of ovarian cancer. Based on a phase I study now a multi-center phase II-trial was conducted.
Study Started
Jan 31
Primary Completion
Mar 31
Study Completion
Sep 30
Last Update
Mar 25

Drug Paclitaxel

Drug Carboplatin

Paclitaxel, Carboplatin Experimental


Inclusion Criteria:

histologically-confirmed epithelial ovarian cancer of FIGO stage IIB - IV
life expectancy of more than three months
ECOG performance status less than 3
laboratory parameters within the normal range, including a glomerular filtration rate (GFR) greater than 60 ml/min, serum creatinine levels below 1.6 mg/dl, liver transaminases less than two times the normal levels, bilirubin concentrations below 1.5 mg/dl, adequate bone marrow function as indicated by a neutrophil count greater than 1,500/µl, and a platelet count greater than 100,000/µl.
written informed consent

Exclusion Criteria:

suffering from secondary malignancy or underlying serious, uncontrolled concurrent medical or psychiatric disease
radiotherapy within 4 weeks for study entry
No Results Posted